🇺🇸 FDA
Patent

US 7429387

Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction

granted A61KA61K31/165A61K31/529

Quick answer

US patent 7429387 (Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction) held by The Regents of the University of Colorado expires Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Sep 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/165, A61K31/529, A61K38/1703, A61K38/4893